Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
QUIZOM in FLT3-ITD AML
NCT03135054Phase 2Unknown
- Sponsor
- The University of Hong Kong
- Start
- Oct 2017
- Primary completion
- Oct 2020
- Modality
- Nucleic Acid-Directed Small Molecules, Covalent Small Molecules, Classical Binding Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of quizartinib and homoharringtonine in acute myeloid leukemia (AML), sponsored by The University of Hong Kong. Primary endpoint: Complete Remission up to 16 weeks. Status: unknown.
02
Drugs
quizartinibhomoharringtonine
03
Conditions
acute myeloid leukemia (AML)
Beyond the preview
Go deeper on NCT03135054.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03135054.